Your browser doesn't support javascript.
loading
TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy.
Liu, Heng-Jia; Lizotte, Patrick H; Du, Heng; Speranza, Maria C; Lam, Hilaire C; Vaughan, Spencer; Alesi, Nicola; Wong, Kwok-Kin; Freeman, Gordon J; Sharpe, Arlene H; Henske, Elizabeth P.
Afiliação
  • Liu HJ; Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Lizotte PH; Belfer Center for Applied Cancer Science, Boston, Massachusetts, USA.
  • Du H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Speranza MC; Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Lam HC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Vaughan S; Harvard Medical School, Boston, Massachusetts, USA.
  • Alesi N; Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Wong KK; Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Freeman GJ; Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Sharpe AH; Belfer Center for Applied Cancer Science, Boston, Massachusetts, USA.
  • Henske EP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
JCI Insight ; 3(8)2018 04 19.
Article em En | MEDLINE | ID: mdl-29669930
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esclerose Tuberosa / Antígeno CTLA-4 / Receptor de Morte Celular Programada 1 / Alvo Mecanístico do Complexo 1 de Rapamicina / Proteína 2 do Complexo Esclerose Tuberosa / Imunoterapia Tipo de estudo: Etiology_studies Limite: Animals Idioma: En Revista: JCI Insight Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esclerose Tuberosa / Antígeno CTLA-4 / Receptor de Morte Celular Programada 1 / Alvo Mecanístico do Complexo 1 de Rapamicina / Proteína 2 do Complexo Esclerose Tuberosa / Imunoterapia Tipo de estudo: Etiology_studies Limite: Animals Idioma: En Revista: JCI Insight Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos